ClinicalTrials.gg
CompletedNCT02594267Updated Jul 27, 2021

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

A Phase 1 interventional study of Pralatrexate Injection in Peripheral T-Cell Lymphoma (PTCL), sponsored by Acrotech Biopharma Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral — none open to participants now, 1 under way, 1 of them phase 3. pralatrexate · Lymphoma, T-Cell, Peripheral.

Enrollment
6th of 11
48 · median 48
Started
2015
with 1 other
Phase 1
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
5 of 11
Acrotech Biopharma Inc.

Among the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral, this one is the 6th largest by enrollment, is one of 2 that started in 2015, is the only one in phase 1, and was the 8th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

None of the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral is open now. The open studies under Lymphoma, T-Cell, Peripheral, anywhere →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral as a file.
02

Study summary

The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).

Read the detailed description

This is a Phase 1, open-label, multicenter, two-part, dose-finding, dose-escalation study.

The study is divided into two parts:

Part 1

Up to five sequential dose cohorts will enroll a maximum of 6 patients each. Escalation of the pralatrexate dose, after CHOP administration (Fol-CHOP), will continue in a traditional 3+3 design, until determination of the MTD. If the MTD is not reached, the Maximum Administered Dose (MAD) of pralatrexate in combination with CHOP will be 30 mg/m2 IV on Days 1 and 8 of each 21-day cycle for up to 6 cycles.

The first cohort will begin with three patients with dose A and CHOP at full dose. If none of the first three patients experiences a Dose-Limiting Toxicity (DLT), the next three patients will be enrolled in next higher dose cohort. If one of the first three patients in the first cohort experiences DLTs, an additional three patients will be enrolled into that cohort. If 2 or 3 of the first 3 patients experience DLTs, then the MTD is not found.

For cohorts 2, 3, 4, and 5, If none of the first three patients experiences a DLT, the next three patients will be enrolled in next higher dose cohort. If one of the first three patients in the first cohort experiences DLTs, an additional three patients will be enrolled into that cohort. If 2 or 3 of the first 3 patients experience DLTs, then the previous cohort will be considered the MTD and up to an additional 10 patients will be enrolled at that dose in Part 2 of the study.

Part 2

Once the MTD for the Fol-CHOP regimen has been established in Part 1 of the study, an additional 10 patients will be treated at the MTD (or MAD if MTD not reached) to confirm tolerability. Additionally, the PK of the established MTD of pralatrexate, when administered with CHOP at full dose, will be evaluated in these 10 patients.

03

Conditions studied

  • Peripheral T-Cell Lymphoma (PTCL)

Keywords

  • PTCL
  • Peripheral T-Cell Lymphoma
  • Folotyn
  • Pralatrexate
  • CHOP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or above
  2. Adequate hematologic, hepatic, and renal function
  3. confirmed, new diagnosis of PTCL
  4. Eligible for CHOP regimen
  5. based on Cheson 2007 criteria
  6. (ECOG) performance status \< 2
  7. Willing to perform at least two methods of
  8. Negative pregnancy test of females with .

Exclusion criteria

Exclusion Criteria:

  1. Active concurrent (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least 5 years.
  2. Congestive heart failure Class III/IV according to the (NYHA) Functional Classification.
  3. Uncontrolled hypertension
  4. Central nervous system (CNS) .
  5. Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment
  6. Major surgery within 30 days prior to enrollment.
  7. Use of any drugs, biologics, or devices within 30 days prior or during the study treatment.
  8. Previous exposure to pralatrexate.
  9. Pregnant or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Finding, Cohort 1

    Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose. The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose. The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose. The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose. The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose. Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1.

    Drug: Pralatrexate Injection

Interventions

  • Drug: Folotyn (Pralatrexate Injection) CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone

    Also known as: Folotyn

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    To evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL)

    Time frame: 126 Days

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs) using CTCAE version 4.03

    Investigator will question the patient at every visit about AEs and intercurrent illnesses.

    Time frame: 126 Days

  2. Objective Response Rate

    To evaluate the Objective Response Rate (ORR) of 6 cycles of Fol-CHOP

    Time frame: 126 Days

  3. Plasma concentration of pralatrexate in combination with CHOP

    Measure the concentration of pralatrexate to evaluate the pharmacokinetics of pralatrexate when given in combination with CHOP using non-compartmental analysis.

    Time frame: 126 Days

  4. Pharmacokinetics: Area Under the Curve (AUC)

    Non-compartmental Analysis

    Time frame: 126 Days

  5. Pharmacokinetics: Maximum Concentration (Cmax)

    Non-compartmental Analysis

    Time frame: 126 Days

  6. Pharmacokinetics: Time to Maximum concentration (Tmax)

    Non-compartmental Analysis

    Time frame: 126 Days

  7. Pharmacokinetics: Clearance (CL)

    Non-compartmental Analysis

    Time frame: 126 Days

07

Study locations

4 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance/University of Washington
    Seattle, Washington 98109, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2017, 16 months.

Of 42 phase 1 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2015
First posted
Nov 3, 2015
StartActual
Nov 10, 2015
Primary completionActual
Apr 7, 2017
CompletionActual
Oct 8, 2020
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02594267
Collaborators
Axis Clinicals Limited
Responsible party
Sponsor
First posted
Nov 3, 2015
Start date
Nov 10, 2015
Primary completion
Apr 7, 2017
Completion
Oct 8, 2020
Last update
Jul 27, 2021

Study contacts

Erard Gilles, MD
study director · Navitas Life Sciences Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion